Dimanche, 24 Septembre 2017
Dernières nouvelles
Principale » Novavax, Inc. (NASDAQ:NVAX) Reports Q1 Revenues of $5.7 million

Novavax, Inc. (NASDAQ:NVAX) Reports Q1 Revenues of $5.7 million

20 Mai 2017

UBS Asset Management Americas Inc. increased its position in shares of Novavax by 4.3% in the third quarter. The average return on assets for companies in the same sector is -11.24. Given that its average daily volume over the 30 days has been 6.56 million shares a day, this signifies a pretty significant change over the norm. During the trading on 05/17/2017, Company's stock ranged from $1.18 to $1.10.

Novavax, Inc. (NVAX) stock price fell -78.76 percent over the past one year, while decreased -20.16 percent during the past 6 months.

Maximum and minimum EPS estimate for the current quarter is projected at $-0.15 and $-0.17, respectively, according to 7 analysts. The stock's market cap is $305.20 million.

Novavax, Inc. (NASDAQ:NVAX) has announced its financial results for the first quarter of 2017.

6 analysts on average are expecting the company to report revenue of $5.7 Million for the current quarter.

The company's revenue in the quarter amounted to $5.7 million which is a 35% increase from the $4.2 that was reported in the same period in 2016. Presently, it has a Return on Equity (ROE) of -787.40%. Novavax's quarterly revenue was up 34.6% on a year-over-year basis. (NVAX) is its Earnings per Share or EPS. Currently, Novavax, Inc.net profit margin for the 12 months is at -1466.36%. (NASDAQ:NVAX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). Cantor Fitzgerald reiterated a "hold" rating and set a $2.00 target price on shares of Novavax in a research note on Friday, January 20th.

Reporters barred from Kushner Companies' visa-for-investment event in China
Almost 90 per cent of EB-5 visas were issued to Chinese nationals in 2014, when the programme reached its quota of 10,000 visas. On Sunday Meyer was introduced in Chinese to investors as a representative of "a famed celebrity investment family".

Some buy side analysts are also providing their Analysis on Novavax, Inc., where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 6 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell.

An earnings forecast is an analyst's outlook for a company's future quarterly or annual earnings.

In related news, insider Stanley C. Erck purchased 50,000 shares of the business's stock in a transaction dated Thursday, May 11th. The shares were acquired at an average cost of $0.84 per share, with a total value of $42,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last three months, insiders have purchased 105,000 shares of company stock worth $90,800. Hedge funds and other institutional investors own 60.36% of the company's stock. In our current pick, Novavax, Inc. The stock plunged -36.42 percent over the past quarter, while declined -23.7 percent over the past six months.

04/07/2015 - Novavax, Inc. had its "fair value" rating reiterated by analysts at Janney Montgomery Scott. Furthermore on 9/16/16 PiperJaffray "Downgrades" the stock to Neutral at $1. Ladenburg Thalmann Financial Services reaffirmed a "neutral" rating on shares of Novavax in a report on Wednesday, March 1st.

Novavax, Inc.is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. JPMorgan Chase & Co. boosted its stake in Novavax by 110.5% in the third quarter. State Street Corp now owns 19,971,040 shares of the biopharmaceutical company's stock worth $25,163,000 after buying an additional 9,947,481 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: "State Board of Administration of Florida Retirement System Has $179,000 Position in Novavax, Inc". NVAX's distance from 200 Day SMA is -56.05%.